Cantor Fitzgerald analyst Elemer Piros raised his price target for Arrowhead Pharmaceuticals to $18 saying the company’s TRiM candidates are “moving impressively quick.” The analyst is “very encouraged” that, in less than two years, Arrowhead began developing the TRiM platform and will have substantial data by November. He reiterates an Overweight rating on the shares following the company’s Q3 results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.